Ringing in 2025 with our work evaluating antibody response to RSV vaccines in immunocompromised persons in @JAMA_current (Editor's choice!). A preliminary product of our ongoing EPOC study (emergingpathogens.jhmi.edu)
jamanetwork.com/journals/jama/… @Hopkins_TRC @AndrewKaraba @Dorry_Segev
jamanetwork.com/journals/jama/… @Hopkins_TRC @AndrewKaraba @Dorry_Segev